Galectin Therapeutics Inc. (GALT)

NASDAQ: GALT · Real-Time Price · USD

1.355

+0.025 (1.88%)

Apr 23, 2025, 4:00 PM EDT - Market closed

Galectin Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Net Income	-47.05	-41.07	-38.78	-30.53	-23.47	Upgrade
Depreciation & Amortization	0.04	0.03	0.03	0.04	0.04	Upgrade
Stock-Based Compensation	2.45	2.26	2.87	2.08	1.8	Upgrade
Other Operating Activities	0.51	1.13	-0.15	0.15	0.09	Upgrade
Change in Accounts Payable	-2.07	2.67	4.24	3.69	2.54	Upgrade
Change in Other Net Operating Assets	4.36	2.01	0.72	0.27	-1.59	Upgrade
Operating Cash Flow	-41.77	-32.97	-31.06	-24.31	-20.6	Upgrade
Long-Term Debt Issued	30	30	10	30	-	Upgrade
Net Debt Issued (Repaid)	30	30	10	30	-	Upgrade
Issuance of Common Stock	1.23	10.03	-	6.81	0.26	Upgrade
Financing Cash Flow	31.23	40.03	10	36.81	0.26	Upgrade
Net Cash Flow	-10.54	7.07	-21.06	12.51	-20.34	Upgrade
Levered Free Cash Flow	-28.94	-20.68	-17.56	-13.23	-11.89	Upgrade
Unlevered Free Cash Flow	-25.48	-18.93	-16.91	-12.92	-11.84	Upgrade
Change in Net Working Capital	1.44	-2.57	-4.16	-3.82	-0.98	Upgrade

Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q